Citigroup
TMBR

Citigroup’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

Citigroup’s Portfolio TMBR Stock Details TMBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-400
Closed -$6K – 6614
2022
Q2 		$6K Buy
400
+390
+3,900% +$5.68K ﹤0.01% 5588
2022
Q1 		$0 Buy
+10
New +$167 ﹤0.01% 6813
2017
Q4 		– Hold
0
– – – 7695
2017
Q3 		– Hold
0
– – – 7519
2017
Q2 		– Hold
0
– – – 7542
2016
Q2 		– Hold
0
– – – 7564
2016
Q1 		– Hold
0
– – – 7878
2015
Q4 		– Hold
0
– – – 7449
2015
Q3 		– Hold
0
– – – 7851

Other funds holding TMBR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

Citigroup's TMBR Position: Q3 2022 in Review

Citigroup sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q3 2022, closing a stake of 400 shares — an estimated $6K sold.

Citigroup first reported a position in TMBR in Q1 2022 and held it in 2 quarters. The position peaked at $6K in Q2 2022. 16 funds tracked by Wall St. Rank hold TMBR as of Q3 2022.

  • Citigroup reported no remaining Timber Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • Citigroup sold 400 Timber Pharmaceuticals, Inc. shares in Q3 2022, an estimated $6K.
  • Citigroup first reported a position in Timber Pharmaceuticals, Inc. in Q1 2022 and held it in 2 quarters.
  • Citigroup's Timber Pharmaceuticals, Inc. position peaked at $6K in Q2 2022.
  • 16 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.